Brief: Valbiotis Announces Positive Results For Val-070 In Hypercholesterolemia

Valbiotis SA

10/07/2018 16:39

July 10 (Reuters) - VALBIOTIS SAS  ALVAL.PA :
    * VALBIOTIS ANNOUNCES POSITIVE RESULTS FROM FIRST PHASE I/II
CLINICAL STUDY OF VAL-070 IN HYPERCHOLESTEROLEMIA
    * RESULTS SUPPORT FUTURE PHASE II CLINICAL STUDIES OF
VAL-070,
WITH BLOOD LDL-CHOLESTEROL AS PRIMARY ENDPOINT
    * VAL-070 IS SAFE AND WELL-TOLERATED
    * PLANS TO ACCELERATE DEVELOPMENT OF VAL-070 AS A POTENTIAL
NEW
FIRST-LINE OPTION TO REDUCE LDL-CHOLESTEROL IN SUBJECTS WITH
MILD TO MODERATE HYPERCHOLESTEROLEMIA
    * CLINICAL DEVELOPMENT AIMS AT APPLYING FOR A PROPRIETARY
HEALTH
CLAIM IN NORTH AMERICA AND EUROPE
    * PLANS TO INITIATE A PHASE II REGISTRATION STUDY DURING
FIRST
HALF OF 2019

Source text for Eikon:  ID:nBw2kgmQPa 
Further company coverage:  ALVAL.PA 

 (Gdynia Newsroom:)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))